Determination of total homocysteine (tHcy) in plasma is becoming an important diagnostic procedure in clinical chemistry because a slightly increased concentration of tHcy in plasma has been discussed as an important independent risk factor for atherosclerotic diseases (1 ). Many methods, mostly by HPLC, have been reported for measuring tHcy (2 ). However, these methods are relatively complex and require highly specialized equipment. Drew Scientific, Inc. (company named for identification purposes only; this evaluation does not constitute an endorsement by CDC) has developed the DS30 tHcy system for measuring tHcy in plasma. We evaluated this new system and compared it with our CDC reference HPLC method (3 ).
Determination of total homocysteine (tHcy) in plasma is becoming an important diagnostic procedure in clinical chemistry because a slightly increased concentration of tHcy in plasma has been discussed as an important independent risk factor for atherosclerotic diseases (1 ) . Many methods, mostly by HPLC, have been reported for measuring tHcy (2 ) . However, these methods are relatively complex and require highly specialized equipment. Drew Scientific, Inc. (company named for identification purposes only; this evaluation does not constitute an endorsement by CDC) has developed the DS30 tHcy system for measuring tHcy in plasma. We evaluated this new system and compared it with our CDC reference HPLC method (3 ) .
The DS30 tHcy system comprises a small HPLC system using a 5-cm reversed-phase column, a tHcy assay reagent set that contains the necessary reagents and calibrators [5 and 20 mol/L homocystine (concentration was equivalent to the free thiol)] and a quality-control (QC) set containing two concentrations of Hcy. The sample preparation requires 200 L of plasma. A batch of 30 samples can be processed within 90 min. After the addition of 10 L of the internal standard (IS; 2-mercaptoethylamine) to 200 L plasma, the mixture of disulfides, mixed disulfides, and protein-bound thiols is reduced using 20 L of tris(2-carboxyethyl)phosphine (TCEP). Protein is precipitated from this solution with trichloroacetic acid, and 100 L of the supernatant is then derivatized with a fluorescent thiol-specific dye [ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate (SBDF) in EDTA/borate buffer] at 60°C for 50 min. The thiol derivatives are separated in a subsequent step by HPLC and detected by their fluorescence. The total run time for a batch of 30 samples is ϳ5-6 h. Quantitative analysis is achieved using a two-point calibration curve with homocystine in an aqueous matrix.
We assessed the within-assay and between-assay imprecision, the recovery of homocystine added to plasma, the linearity of increasing tHcy concentration in plasma, the dilution linearity, and the limit of detection. We also compared the results of 260 plasma samples obtained by the DS30 system to the results we obtained previously for these samples by our CDC in-house HPLC method. These samples were a subset of the EDTA plasma samples for the National Health and Nutrition Examination Survey 1999ϩ, which includes an omnibus informed consent and Human Subjects Review protocol.
The within-assay imprecision (CV) for five replicate measurements was Ͻ2% for the two concentrations of DS30 QC samples and the three concentrations of CDC QC pools. The between-assay imprecision was as follows:
5.8% for DS30 QC low (n ϭ 21 days; mean tHcy, 13.4 mol/L), 4.6% for DS30 QC high (n ϭ 21 days; mean tHcy, 23.3 mol/L), 3.8% for CDC QC low (n ϭ 27 days; mean tHcy, 7.3 mol/L), 3.2% for CDC QC medium (n ϭ 27 days; mean tHcy, 14.7 mol/L), and 4.8% for CDC QC high (n ϭ 16 days; mean, tHcy, 31.8 mol/L).
Homocystine was added to a plasma sample at six different concentrations in duplicate: 0, 6.25, 12.5, 25, 50, and 100 mol/L (concentrations equivalent to the free thiol). The mean recovery (SD) was 101.7% Ϯ 1%. The linearity of increasing tHcy concentrations in plasma was very good up to 100 mol/L (y ϭ 1.028x Ϫ 0.127; r 2 ϭ 1.000).
The DS30 HPLC system is programmed such that peak recognition of tHcy and the IS depends on a minimum concentration of cysteine and cysteinyl-glycine. We found that this minimum concentration was 50 mol/L cysteine and 7.5 mol/L cysteinyl-glycine. Thus, dilution of plasma Ͼ1:4 with saline or water leads to a loss of recognition of the peaks. Dilution of a plasma sample (tHcy concentration of ϳ30 mol/L) with a solution containing 200 mol/L cysteine and 30 mol/L cysteinylglycine [these concentrations of cysteine and cysteinylglycine correspond to an average concentration found in the population (4 )] at 1:2, 1:4, 1:8, and 1:16 gave very good linearity (y ϭ 0.999x ϩ 0.115; r 2 ϭ 0.999). The difference between the measured and the expected concentrations was Ͻ3%. Diluting the same plasma with either saline or water at 1:2 and 1:4 also gave very good linearity; however, the difference between the measured and the expected concentrations was 5-10%. The limit of detection for tHcy was ϳ2 mol/L.
The retention times for each compound were stable over the 24 assays we performed over 4 months. The variation of the retention times for all compounds was 3%. The variation (CV) of the IS heights for all samples, except for the DS30 QC samples, over the period of evaluation was 10.5%. The DS30 QC samples gave consistently lower heights (ϳ25% lower) for the IS than all other samples. The reason for this was that the DS30 QC samples were not EDTA plasma, but heparin plasma, and apparently the anticoagulant influenced the obtained peak height. However, because ratios between tHcy and the IS heights were used for quantification, this should not have influenced the final result. However, users should be alerted that we tested only the suitability of the DS30 assay for EDTA plasma samples. We believe the use of this assay for matrices other than EDTA plasma should be evaluated first.
An extensive method comparison was performed between the DS30 tHcy system and the CDC in-house HPLC method. If samples were not analyzed simultaneously with both methods, they were stored at Ϫ70°C for not Ͼ6 months between the assays. The performance of the CDC reference HPLC assay and the validation results were described in detail in a separate article (3 ). tHcy concentrations determined for 260 plasma samples from healthy subjects gave good correlation between the two methods: y ϭ 1.018x ϩ 0.280 (r 2 ϭ 0.976). The Bland-Altman plot in Ninety-five percent of tHcy determinations by DS30 were 1.10 -1.89 mol/L higher than concentrations determined by the CDC HPLC method.
In conclusion, the DS30 tHcy system showed withinassay and between-assay imprecision (CV Ͻ6%) comparable to other frequently used HPLC assays (3) (4) (5) and the Abbott IMx assay (6 ) . The DS30 tHcy system also showed complete recovery of added tHcy and a linearity up to 100 mol/L. Dilution of plasma with a solution containing cysteine and cysteinyl-glycine produced very good linearity. However, dilutions of plasma with water or saline should not exceed 1:4 to avoid misidentification of peaks resulting from undetectable cysteine and cysteinyl-glycine peak heights. Samples with a tHcy concentration up to maximum 400 mol/L can be measured after 1:4 dilution with water or saline. However, we recommend verifying the printout with regard to peak identification, retention times, and peak heights to avoid mislabeling peaks (especially with diluted samples). The comparison of this method with the CDC reference HPLC method on samples up to 25 mol/L tHcy revealed only a minimal bias (0.39 mol/L). Therefore, the DS30 tHcy system performed accurately and precisely, and thus might be well suited for routine measurement for tHcy where complex HPLC analysis is not feasible. (1, 3 ) and to misclassify some exudates as transudates (3, 4 ) .
Protein analysis has been proposed to improve classification into transudates or exudates based on the assumption that large proteins are present only in exudates because of the increased capillary permeability (1 ). Agarose gel electrophoresis (AGE) has been the standard procedure for serum protein fractionation for Ͼ30 years, but it is laborious and methods do not agree (6 -8 ) . Capillary zone electrophoresis (CZE) is an attractive alternative (6, 9, 10 ) and avoids between-protein differences in dye affinity.
We evaluated the Beckman Paragon CZE TM 2000 system, a multicapillary instrument for automated serum protein electrophoresis (7, 8 ) , for quantitative fractionation of proteins in body fluids.
For method comparison, leftover samples from 49 pleural and 11 ascitic fluids from 47 inpatients were used. There were no preset selection criteria regarding age, sex, or type of disease (11 ); however, only 37 pleural effusions were classified as transudates or exudates after exclusion of patients lacking definitive clinical diagnosis (n ϭ 5), patients with multiple diagnoses (n ϭ 3), or in case of interference by radioopaque agents (n ϭ 4). A serum sample was collected simultaneously with the pleural 
